Cloudreach and AWS Sign Strategic Collaboration Agreement to Accelerate Global Cloud Adoption
11.8.2021 12:00:00 EEST | Business Wire | Press release
Cloudreach, a leading independent cloud services provider, and Amazon Web Services (AWS), today unveiled a new Strategic Collaboration Agreement. The wide-ranging agreement will mean an acceleration of the companies’ joint go-to-market proposition, along with investments in Cloudreach software innovation, geographical expansion and the launch of a Talent Academy.
This agreement builds on the well-established 12-year relationship between Cloudreach and AWS. Cloudreach will expand within North America and Europe including into new territories Canada, Poland, Spain and the Nordics. In addition, Cloudreach will make significant investments in software, further developing its SMART Migration™ and SMART Modernization™ services. These services are designed to accelerate enterprise cloud adoption through intelligent automation and will help more customers to realize the benefits of AWS services with far greater efficiency.
Cloudreach CEO, Brooks Borcherding, said: “After 12 years of collaboration with AWS, we’re excited to be entering this new phase of growth. Together, we’re focused on delivering the promise of the cloud through new software-driven capabilities coupled with industry-best practices and expertise. For our customers this will mean adopting AWS cloud more efficiently and with greater confidence, achieving a faster time to value.”
Launch of Cloudreach Talent Academy
A key initiative within the agreement is the launch of a Talent Academy. The Academy is designed to train hundreds of diverse and promising candidates to become the next generation of cloud professionals. For entry into the program, Cloudreach will look for candidates with a passion for building their career in cloud, even if they do not have a technical background, and fast-track their technical development.
The program will bring more talent into the AWS community, offering candidates a path to acquire and upskill their AWS capabilities. The Talent Academy is unique in its emphasis on recruiting from a diverse pool of candidates who traditionally have not selected technical career paths. Cloudreach expects hundreds of candidates to become AWS-certified and get the hands-on experience to become cloud consultants, engineers, architects, and developers.
“Cloudreach is committed to addressing underrepresentation and the lack of diversity within the technology workforce and cloud industry. This purpose-driven investment is one of the most exciting aspects of this collaboration with AWS. We’re dedicated to be helping future professionals develop their careers where they will solve complex business challenges for our joint customers,” added Borcherding.
Doug Yeum, Head of Worldwide Channels and Alliances at AWS, said: “We are delighted to build upon the 12-year relationship with AWS Premier Partner, Cloudreach. This collaboration means AWS can bring the highest level of cloud native expertise to an even wider audience with Cloudreach, significantly accelerating the pace of global cloud adoption. We are also particularly appreciative of Cloudreach’s focus on expanding the diverse talent pool of AWS-skilled professionals, which aligns with our leadership principles as a company.”
This engagement will provide AWS and Cloudreach customers with compelling new SMART Migration™ and SMART Modernization™ service offerings to dramatically accelerate cloud adoption and reduce time-to-value by 40%. These new offerings leverage both Cloudamize, a leading planning, assessment, and migration automation software, and Sunstone, a cloud modernization machine learning engine to make continuous modernization recommendations for legacy and cloud deployed services.
Marie Measures, Chief Technology Officer at Sanne Group, the alternative asset fund administrator, said: “The possibilities are endless when you engage with an AWS Partner that’s flexible, easy to work with, and shares your organization’s values. We want to move quickly along our cloud journey and, thanks to Cloudreach and AWS, we have a well-structured transformational roadmap.”
For more details about the collaboration between AWS and Cloudreach, please visit: www.cloudreach.com/en/partners/aws-premier-consulting-partner/
– ENDS –
About Cloudreach
Cloudreach is the world’s leading independent cloud services company. Our mission is to deliver the promise of cloud and drive extraordinary value for our customers. Cloudreach helps enterprises win competitive advantage through successful cloud transformation. With more than 10 years of cloud native experience, we’ve built an unmatched depth and breadth of expertise in cloud technologies and their application to business. For more information about our work, visit www.cloudreach.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210811005334/en/
Contact information
Press Contact
Rahim Hakimi
Email: rahim.hakimi@cloudreach.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom